Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jilin Huakang Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and manufacturing of modern Traditional Chinese Medicine (TCM) and herbal-based therapeutics. As a key subsidiary of China Resources Sanjiu (CR Sanjiu), the company focuses on high-prevalence therapeutic areas such as cardiovascular and cerebrovascular diseases, gynecology, and pediatrics. Its flagship products, including Shuxuening Injection and Ginkgo Biloba Leaf Extract Injection, are market leaders in the Chinese hospital channel. The company is recognized for its commitment to TCM modernization, utilizing advanced extraction and purification technologies to produce standardized, clinically-proven treatments. Jilin Huakang operates large-scale GMP-certified facilities and maintains a robust R&D pipeline aimed at expanding its portfolio of evidence-based TCM products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Huakang Pharmaceutical.